Big Pharma's Top 5 Emerging Market Deals

With pharmaceutical sales in major markets like the United States, Europe and Japan slowing, a number of big drugmakers have looked outside of traditional territories to emerging markets. Eastern Europe, Russia, South America, the Middle East and Asia have all become sought-after markets as Big Pharma begins its emerging markets land-grab.

Below are the top five emerging market deals in the last 12 months. GlaxoSmithKline, which has been particularly aggressive about making deals in foreign markets, has three of our top five deals. But Abbott's $3.7 billion deal for India's Priamal takes the top spot. Click here to see the details. Report >>

1. Abbott and Piramal
2. GSK and Laboratorios Phoenix
3. Novartis and Zhejiang Tianyuan
4. GSK and Amgen
5. GSK and Dong-A

Erica Teichert also contributed to this report.

Read more on

Suggested Articles

At one point, Novartis even offered up $90 apiece for the inclisiran developer but would later say even $85 was too much, a securities filing shows.

Sanofi spent months hyping its Tuesday investor event, and new CEO Paul Hudson certainly laid out a different vision for the drugmaker at the confab.

After more than 10 years as partners, Sanofi and Regeneron are splitting up their deal to comarket PCSK9 med Praluent and immunology drug Kevzara.